DHR · News · 20260728N

Guidance / Outlook

DANAHER CORP /DE/ · 2026-07-28 · Importance 62 · Surprise 68

Danaher’s third-party-reported outlook calls for Q3 2026 revenue growth of 2%–3%, reflecting a headwind in respiratory testing. The company reportedly expects high-single-digit growth in its bioprocessing business despite ongoing market concerns. The outlook indicates near-term pressure in Diagnostics may offset stronger Biotechnology demand during the quarter.

Key facts

• Jefferies maintained a Buy rating on Danaher with a $210.00 price target and analysts' average price target for Danaher was $219.78. source